CAS: 898537-18-3; (2S,3R,4R,5S,6R)-2-(5-(4-Ethoxybenzyl)-2-Methoxy-4-Methylphenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Thiopyran-3,4,5-Triol

📜(1S)-1,5-Anhydro-2,3,4,6-Tetra-O-Benzyl-1-[5-(4-Ethoxybenzyl)-2-Methoxy-4-Methylphenyl]-1-Thio-D-Glucitol置于20% Palladium Hydroxide On Carbon,氢气体系中,用 乙醇,乙酸乙酯 作为反应溶剂,化学反应 48.0H,以81%的收率获得产物鲁格列净
参考文献:(1 S)-1,5-脱水-1-[5-(4-乙氧基苄基)-2-甲氧基-4-甲基苯基]-1-硫代-D-葡萄糖醇(ts-071)是有效的选择性钠盐用于2型糖尿病治疗的依赖性葡萄糖共转运蛋白2(sglt2)抑制剂
标题:(1 S)-1,5-脱水-1-[5-(4-乙氧基苄基)-2-甲氧基-4-甲基苯基]-1-硫代-D-葡萄糖醇(ts-071)是有效的选择性钠盐用于2型糖尿病治疗的依赖性葡萄糖共转运蛋白2(sglt2)抑制剂
摘要:一种新颖的支架的衍生物,C ^-苯基-1-硫代d-Glucitol,制备并评价为钠依赖性葡萄糖协同转运蛋白(sglt)2个sglt1抑制活性.优化芳环上的取代基可得到五种具有有效和选择性sglt2抑制活性的化合物.评价了这些化合物的体外人类代谢稳定性,人类血清蛋白结合(spb)和caco-2渗透性.它们中,(1个小号)-1,5-脱水-1-[5-(4-乙氧基苄基)-2-甲氧基-4-甲基苯基]-1-硫代d-Glucitol(3P)显示出强效的sglt2抑制活性(Ic 50 = 2.26 Nm),选择性是sglt1的1650倍.复合3P对冷冻保存的人肝清除率,较低的spb和适度的caco-2通透性显示出非常好的代谢稳定性.由于3P应该具有可接受的人体药代动力学(pk)特性,因此它可能是治疗2型糖尿病的临床候选药物.我们观测到化合物3P在动物中表现出降血糖作用,出色的尿葡萄糖排泄特性和有
DOI:10.1021/jm901893X

专利信息

专利号:US-9018249-B2
优先权日:2011-09-13
标题 :SGLT inhibitors
发明人：JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR
权利人:JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR; PANACEA BIOTEC LTD
摘要:The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

专利号:US-2014228303-A1
优先权日:2011-06-13
标题 :Novel sglt inhibitors
发明人：JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR
权利人:JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR; PANACEA BIOTEC LTD
摘要:The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

专利号:US-11565990-B2
优先权日:2020-12-04
标 题:Preparation of 4-bromo-2-(4′-ethoxyphenyl)-1-chlorobenzene
发明人：HU LIN; XU TAO; QIU XIAOLONG; LI XIAOYUE; ZUO ZHIWEI; LIU WENBO; CHU LINGLING; YUAN XIMENG; ZOU PING
权利人:WISDOM PHARMACEUTICAL CO LTD
摘要:A more environmentally friendly synthesis method of 4-bromo-2-(4′-ethoxyphenyl)-1-chlorobenzene with simplified steps provides a more effective synthetic strategy for producing key intermediates of SGLT-2 inhibitors such as dapagliflozin, sotagliflozin, and ertugliflozin. In the presence of trifluoroacetic anhydride, 5-bromo-2-chlorobenzoic acid and phenetole are selected to complete a direct acylation reaction under the catalysis of boron trifluoride diethyl etherate, and triethylsilane is added thereinto without treatment for one-pot reaction to obtain a target compound 4-bromo-2-(4′-ethoxyphenyl)-1-chlorobenzene.

专利号:EP-2947077-A1
优先权日:2014-05-19
标 题 :Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides